Abstract: A pharmaceutical combination and an application thereof. The pharmaceutical combination comprises a PI3K inhibitor and an immune checkpoint inhibitor, wherein the PI3K inhibitor is selected from a compound represented by formula (I), linperlisib, samotolisib, copanlisib, SHC014748M, pilaralisib, buparlisib, taselisib, YZJ-0673, gedatolisib, omipalisib, bimiralisib, voxtalisib, AL58805, and HEC68498, and pharmaceutically acceptable salts thereof, and the immune checkpoint inhibitor is a PD-1/PD-L1 inhibitor. The compound represented by formula (Ia) has a high inhibitory effect on PI3K? and PI3K? kinases, and the pharmaceutical combination uses a PI3K inhibitor and a PD-1 inhibitor in combination, thereby effectively improving the inhibitory effect on tumors, and solving the problem of drug resistance of PD-1/PD-L1 inhibitors.

Abstract: Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.

Abstract: The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucose kinase activator or a pharmaceutical salt of same, an isotope marker of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed-dose compound preparation, and a preparation method for and uses of the pharmaceutical composition and of the fixed dose compound preparation.

Abstract: Disclosed is the use of a pyridone derivative containing a heteroatom cyclobutane substituent. Disclosed is the use of substance A in the preparation of a drug. Substance A is a compound as represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The drug is the drug for treating and/or preventing diabetic feet. The disclosed substance A or the drug containing substance A has good activity on patients with a diabetic foot.

Abstract: Provided is the use of a pyrrolopyrimidine compound. The structure of the pyrrolopyrimidine compound is as represented by formula I, which compound has the effect of inhibiting the phosphorylation of STAT, and has a good prevention or treatment effect on suppurative myelitis, acute myelitis, encephalomyelitis or autoimmune diseases.

Abstract: The present invention relates to a pharmaceutical combination, comprising a glucokinase activator or a pharmaceutically acceptable salt, isotopic label, crystal form, hydrate, solvate, diastereomer, or enantiomer thereof and an SGLT-2 inhibitor. The present invention further relates to a pharmaceutical composition, a fixed-dose combination preparation, and preparation methods and uses thereof.

Abstract: Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.

Abstract: Use of a pyrido[1,2-a]pyrimidone analogue. Specifically disclosed is use of a compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing cancers in the digestive tract system. The compound I or the pharmaceutically acceptable salt thereof has good antitumor activity against one or more of head and neck cancer, hepatocellular cancer, colorectal cancer, esophageal cancer, gastric cancer and nasopharyngeal cancer.

Abstract: An application of a pyrido[1,2-a]pyrimidinone analog or a pharmaceutically acceptable salt thereof in the preparation of a drug, the drug being used to treat and/or prevent one or more among PIK3CA-mutated breast cancer, PIK3CA-mutated ovarian cancer, PIK3CA-mutated endometrial cancer, PIK3CA-mutated cervical cancer, and PIK3CA-mutated bladder cancer.

Abstract: Disclosed are a salt of a pyrrolopyrimidine compound, a crystalline form thereof, and an application thereof. Specifically provided are a crystal form of the compound represented by the formula I, a salt thereof, and a hydrate of the salt thereof, and a crystalline form of the compound represented by the formula (I), a method for preparation of the salt, and an application thereof, furthermore, the salt and crystalline form of the present invention are stable in nature and have good hygroscopicity, and have good prospects for finished-drug applications.

Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

Abstract: A system for controlling the amount of a liquid carbon source released to a constructed wetland, includes: a carbon source pool, a carbon source pipe, a peristaltic pump, a programmable logic controller (PLC), a computer, a first flow meter, a first chemical oxygen demand (COD) sensor, a first total nitrogen (TN) sensor, a second TN sensor, a second COD sensor, an inlet pipe, and an outlet pipe. The first flow meter, the first COD sensor, and the TN sensor are disposed on the inlet pipe; the second COD sensor and the second TN sensor are disposed on the outlet pipe; the inlet pipe and the outlet pipe are connected to the constructed wetland; the carbon source pipe is connected to the carbon source pool via the peristaltic pump; the computer, the peristaltic pump, the first flow meter, and all sensors are connected to the PLC controller.

Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

Abstract: An application of a heterocyclic compound. An application of a substance Y in the preparation of drugs for raising blood sugar. The compound can be used to raise blood sugar and treat hypoglycemia or congenital hyperinsulinism.

Abstract: Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.

Abstract: Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.

Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

Abstract: A pharmaceutical combination comprises a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotope labeled form thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof and an ?-glucosidase inhibitor. A pharmaceutical composition, a fixed dose combination formulation, a preparation method for and the use of the pharmaceutical composition and the fixed dose combination formulation.

Abstract: The present invention relates to a pharmaceutical combination, comprising a glucokinase activator or a pharmaceutically acceptable salt, isotopic label, crystal form, hydrate, solvate, diastereomer, or enantiomer thereof and an SGLT-2 inhibitor. The present invention further relates to a pharmaceutical composition, a fixed-dose combination preparation, and preparation methods and uses thereof.

Abstract: The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucose kinase activator or a pharmaceutical salt of same, an isotope marker of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed-dose compound preparation, and a preparation method for and uses of the pharmaceutical composition and of the fixed dose compound preparation.